Last reviewed · How we verify

PegIFN-2b — Competitive Intelligence Brief

PegIFN-2b (PegIFN-2b) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pegylated interferon-beta. Area: Immunology / Virology.

marketed Pegylated interferon-beta Interferon-beta receptor (IFNAR) Immunology / Virology Biologic Live · refreshed every 30 min

Target snapshot

PegIFN-2b (PegIFN-2b) — Merck Sharp & Dohme LLC. PegIFN-2b is a pegylated interferon-beta that activates interferon-beta receptors to enhance innate and adaptive immune responses against viral infections and certain malignancies.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PegIFN-2b TARGET PegIFN-2b Merck Sharp & Dohme LLC marketed Pegylated interferon-beta Interferon-beta receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pegylated interferon-beta class)

  1. Merck Sharp & Dohme LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PegIFN-2b — Competitive Intelligence Brief. https://druglandscape.com/ci/pegifn-2b. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: